Neuphoria Therapeutics Inc (NEUP)vsNovartis AG ADR (NVS)
NEUP
Neuphoria Therapeutics Inc
$4.84
+2.98%
HEALTHCARE · Cap: $24.27M
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates -426456714% more annual revenue ($56.58B vs $-13,267). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NEUP
Hold47
out of 100
Grade: D+
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NEUP.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 110513.0%
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Operating Margin, Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
NEUP profiles as a value stock while NVS is a declining play — different risk/reward profiles.
NEUP is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (49/100 vs 47/100), backed by strong 23.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is an innovative biotechnology company at the forefront of developing pioneering therapies for mental health disorders utilizing psychedelic compounds and cutting-edge drug delivery technologies. With a robust pipeline of preclinical candidates, Neuphoria is strategically positioned to address critical unmet needs in mental health care, reflecting the growing demand for effective treatment options in this sector. As a leader in the expanding psychedelic therapy market, Neuphoria presents a unique investment opportunity for institutional investors looking to capitalize on transformative trends in healthcare that have the potential to redefine the treatment landscape for mental health conditions.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?